BIOMAT Database Logo BIOMAT Database Logo

Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. 1997

H Bleiberg, and T Conroy, and B Paillot, and A J Lacave, and G Blijham, and J H Jacob, and L Bedenne, and M Namer, and P De Besi, and F Gay, and L Collette, and T Sahmoud
Institut J. Bordet, Brussels, Belgium.

Patients with measurable or evaluable locally advanced or metastatic squamous cell carcinoma of the oesophagus were treated with cisplatin (CDDP), 100 mg/m2, combined with 5-fluorouracil (5-FU) at a dose of 1000 mg/m2 as a continuous infusion from days 1-5 (Arm A) or with CDDP alone (Arm B). Cycles were repeated every 3 weeks. 92 patients were randomised centrally, 88 were eligible. The response rate was 35% (95% CI (confidence interval), 20-54%) in Arm A and 19% (95% CI, 8-35%) in Arm B. One complete response was observed in each arm. The median duration of survival was 33 weeks and 28 weeks for Arm A and Arm B, respectively. Haematological and non-haematological toxicities were more frequent and more severe in Arm A. The most prominent toxicities were grade 4 aplasia and septicaemia (2), meningeal haemorrhage (1), cerebrovascular accident (3) and ischaemia of the lower limbs (1) all occurring in Arm A. Overall, seven treatment-related deaths (16%) were observed in Arm A, none in Arm B. The severe side-effects induced by the combination suggest that, currently, no standard chemotherapy can be recommended for patients with advanced squamous cell oesophageal cancer.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004938 Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS. Cancer of Esophagus,Esophageal Cancer,Cancer of the Esophagus,Esophagus Cancer,Esophagus Neoplasm,Neoplasms, Esophageal,Cancer, Esophageal,Cancer, Esophagus,Cancers, Esophageal,Cancers, Esophagus,Esophageal Cancers,Esophageal Neoplasm,Esophagus Cancers,Esophagus Neoplasms,Neoplasm, Esophageal,Neoplasm, Esophagus,Neoplasms, Esophagus
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

H Bleiberg, and T Conroy, and B Paillot, and A J Lacave, and G Blijham, and J H Jacob, and L Bedenne, and M Namer, and P De Besi, and F Gay, and L Collette, and T Sahmoud
Cisplatin + 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: a randomized study.
October 1988, European journal of cancer & clinical oncology,
H Bleiberg, and T Conroy, and B Paillot, and A J Lacave, and G Blijham, and J H Jacob, and L Bedenne, and M Namer, and P De Besi, and F Gay, and L Collette, and T Sahmoud
Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: a randomised phase II study.
June 2005, European journal of cancer (Oxford, England : 1990),
H Bleiberg, and T Conroy, and B Paillot, and A J Lacave, and G Blijham, and J H Jacob, and L Bedenne, and M Namer, and P De Besi, and F Gay, and L Collette, and T Sahmoud
Phase II study of cisplatin, 5-FU, and allopurinol in advanced esophageal cancer.
July 1986, Cancer treatment reports,
H Bleiberg, and T Conroy, and B Paillot, and A J Lacave, and G Blijham, and J H Jacob, and L Bedenne, and M Namer, and P De Besi, and F Gay, and L Collette, and T Sahmoud
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
June 1993, Cancer,
H Bleiberg, and T Conroy, and B Paillot, and A J Lacave, and G Blijham, and J H Jacob, and L Bedenne, and M Namer, and P De Besi, and F Gay, and L Collette, and T Sahmoud
Chemotherapy with 5-fluorouracil (5-FU) and cisplatin or 5-FU, cisplatin, and vinblastine for advanced non-small cell lung cancer. A randomized phase II study of the cancer and leukemia group B.
June 1991, Cancer,
H Bleiberg, and T Conroy, and B Paillot, and A J Lacave, and G Blijham, and J H Jacob, and L Bedenne, and M Namer, and P De Besi, and F Gay, and L Collette, and T Sahmoud
Phase II study of cisplatin, gemcitabine and 5-fluorouracil in advanced pancreatic cancer.
March 2004, Annals of oncology : official journal of the European Society for Medical Oncology,
H Bleiberg, and T Conroy, and B Paillot, and A J Lacave, and G Blijham, and J H Jacob, and L Bedenne, and M Namer, and P De Besi, and F Gay, and L Collette, and T Sahmoud
Randomized phase II study of a combination of cisplatin (DDP), 5-fluorouracil (5-FU), and allopurinol (HPP) versus 5-FU in advanced colorectal carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group study.
January 1990, Cancer investigation,
H Bleiberg, and T Conroy, and B Paillot, and A J Lacave, and G Blijham, and J H Jacob, and L Bedenne, and M Namer, and P De Besi, and F Gay, and L Collette, and T Sahmoud
Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie.
October 2009, Annals of oncology : official journal of the European Society for Medical Oncology,
H Bleiberg, and T Conroy, and B Paillot, and A J Lacave, and G Blijham, and J H Jacob, and L Bedenne, and M Namer, and P De Besi, and F Gay, and L Collette, and T Sahmoud
5-Fluorouracil (5-FU), methyl-CCNU, and vincristine in the treatment of advanced colorectal cancer: phase II study utilizing weekly 5-FU.
November 1976, Cancer treatment reports,
H Bleiberg, and T Conroy, and B Paillot, and A J Lacave, and G Blijham, and J H Jacob, and L Bedenne, and M Namer, and P De Besi, and F Gay, and L Collette, and T Sahmoud
Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2.
November 1998, Cancer immunology, immunotherapy : CII,
Copied contents to your clipboard!